What on earth are you yourself waffling on about goldfing?
I could retort to the utter tosh you have write on a regular basis, but it is clear from others responses to you that they think the same. You'r two slices short of a sandwich squire. Two weeks ago you claimed we had approvals from MHRA and slatted anyone one said we didn't. Yet here we are, with no official notification and nothing on any website to back up your extravagant bull.
The rns to which you refer does not state we have approval for phase 1. It states the "Company is informed by the CTPT that it could proceed now, but the CTPT have recommended that a further stability and sterility study be completed to further strengthen the compound's data package and permit the future rapid progress towards a phase 2 efficacy study." Nothing to do with the MHRA.
We don't have approval for ANY phase atm. By all means point the rns you claim it's in, I may have missed it, but I'm pretty darn sure I haven't.
Hi, I was not talking about an EXTENDED" studies,the original application was for Phase1b,which was approved by MHRA and we could have started it(as per RNS).UCH Clinicians felt this could go futher and be fairer to the patients if we could combine it with Phase2.Then the Stability/Sterility issue came to the fore and VAL201 had to have further tests conducted,which I believe by now should have been resolved.ATB-Stach
The 10th June rns clearly states that ValiRx have "submitted an application to the Medicines and Healthcare Products Regulatory Agency ("MHRA") for a phase I/II extended clinical study, or trial".
It will come in the next couple of weeks I think. Then we've got 8 weeks or there abouts for initial findings.
If they are good we could attract a licencing deal. Last years top 50 deals provided average upfront payments of $99m. Oncology attracts a premium. Unmet clinical needs being met would attract a rather large premium in my book. So you could say we might attract a MCAP of £60m-£100m. That's 6-10 times higher than where we are today. Not a bad return! Put it this way, I would have a wedge in my back pocket! :)
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.